Incyte (MIL:1INCY) FFO


MIL:1INCY Incyte Corp MIL:1INCY
62 GF Score
Price €101.20
GF Value €88.40
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte FFO?

FFO (Funds from operations) only applies to REITs.

MIL:1INCY
62GF Score
Incyte Corp MIL:1INCY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Incyte (MIL:1INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of €101.20 is trading 14.5% above its estimated GF Value™ of €88.40. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MIL:1INCY:

  • FFO:
  • GF Value™: €88.40 vs. price of €101.20 (14.5% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the MIL:1INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
62GF Score

Get the complete analysis for MIL:1INCY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€101.20
Price
€88.40
GF Value